<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819910</url>
  </required_header>
  <id_info>
    <org_study_id>C.2007.122</org_study_id>
    <nct_id>NCT00819910</nct_id>
  </id_info>
  <brief_title>Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)</brief_title>
  <acronym>RAFAEL</acronym>
  <official_title>Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmad Slim</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brooke Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The design of the study will be randomized, double blind trial, which will examine the
      effects of Rosiglitazone on the fasting triglycerides (TG), high-density lipoprotein (HDL),
      low-density lipoprotein (LDL), and plasma concentrations of apolipoproteins A-I, A-II, and
      C-III as compared to Fenofibrate and placebo. This study will also assess the synergistic
      effect of Rosiglitazone and Fenofibrate on the same parameters. Data from this study will
      help clarify whether Rosiglitazone favorably impacts plasma lipid and lipoprotein
      concentrations through improving insulin sensitivity and glycemic control, or by directly
      influencing the synthesis of the apolipoproteins that are responsible for very-low-density
      lipoprotein (VLDL) and HDL metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of patients with type 2 Diabetes Mellitus (DM) consists of reducing hyperglycemia
      through diet, exercise, oral drug therapy or insulin (1). The Thiazolidinedione (TZDs), which
      include Troglitazone (withdrawn by the FDA), Rosiglitazone, and Pioglitazone, correct
      hyperglycemia by increasing insulin sensitivity in both the liver (2, 3) and skeletal muscles
      (4,5). Although TZDs improve glycemic control in type 2 diabetic subjects, when these agents
      are administered to non-diabetic subjects they do not affect fasting plasma glucose levels.
      Nolan et al. (6) observed no effect on the plasma glucose levels of non-diabetic subjects
      treated with Troglitazone 200 mg twice daily.

      Clinical trials using TZDs in type 2 diabetic subjects have observed that these agents also
      favorably impact plasma lipid and lipoprotein concentrations. A recent study comparing the
      efficacy of adding Metformin (850 mg, once or twice daily) or Troglitazone (200 mg, once or
      twice daily) to Glyburide (10 mg, twice daily) on glycemic control in type 2 diabetic
      patients (n=22), reported that after 4 months of treatment, Metformin did not induce
      significant changes in LDL-C, LDL size, HDL-C, Triglycerides or Plasminogen Activator
      Inhibitor-1 (PAI-1), but decreased C-reactive protein (CRP) by 33%. Interestingly,
      Troglitazone increased the size of LDL and the mean LDL-C level (+10%), but decreased the
      Triglyceride (-22%) and CRP (-60%) concentrations (7). Following eight weeks of treatment
      with Rosiglitazone (4mg, twice daily) in 243 type 2 diabetic patients, the mean HDL-C
      increased by 6% and TG by 2%. The increase in the LDL-C concentration (9%) was accompanied by
      a shift in small, dense LDL to large, buoyant LDL in 52% of the treated subjects. The shift
      in LDL size occurred independent of a significant Triglyceride reduction, which is in
      contrast to several studies reporting that increases in LDL size are significantly correlated
      with a decrease in the plasma concentrations of total and very low density lipoproteins
      (VLDL) Triglycerides (8-10).

      The mechanism involved in the plasma lipid and lipoprotein changes induced by TZDs remains
      unclear. It is possible that these agents indirectly alter plasma lipid and lipoprotein
      levels indirectly by improving insulin sensitivity and glycemic control, or directly by
      influencing lipoprotein synthesis and/or catabolism.

      In type 2 Diabetes Mellitus, hepatic synthesis of Triglycerides is increased and peripheral
      catabolism is decreased. The primary metabolic defect causing the hypertriglyceridemia is
      peripheral insensitivity to the action of insulin, accompanied by hyperinsulinemia. The
      insulin insensitivity inhibits the synthesis and activity of lipoprotein lipase and
      consequently impairs peripheral catabolism of Triglyceride-rich lipoproteins (VLDL and
      Chylomicrons) (11-12). Since hepatocytes remain sensitive to the action of insulin, the
      hyperinsulinemia suppresses beta-oxidation and shunts free fatty acids entering the liver
      into the synthesis of Triglycerides. Therefore, hepatic production of Triglycerides (i.e.
      VLDL) is increased at the same time peripheral catabolism is impaired. The result is
      hypertriglyceridemia with a reciprocal decease in HDL-C concentration. By reducing insulin
      resistance and plasma insulin levels, TZDs would decrease hepatic Triglyceride production and
      enhance peripheral catabolism of Triglycerides, resulting in plasma reduction and a
      reciprocal increase in the HDL-C level.

      Recently, it has been recognized that circulating levels of Triglyceride and HDL-C are
      influenced by the activities of Peroxisome Proliferator Activator Receptors (PPARs). PPARs
      constitute a super family of nuclear hormone receptors and are ligand-activated transcription
      factors. When activated, they transmit signals from intra-cellular lipid-soluble factors
      (e.g. fatty acids, hormones, vitamins) to genes in the nucleus by binding to DNA at specific
      response elements (13). Three distinct PPARs, termed alpha, beta, and gamma modulate
      intracellular lipid and glucose metabolism through controlling gene expression when activated
      (14). Specifically when PPAR-alpha is activated, gene expression for the synthesis of
      ApoC-III, lipoprotein lipase, ApoA-I and ApoA-II are impacted. ApoC-III is a specific
      inhibitor of peripheral lipoprotein lipase and competes with ApoE for space on the surface of
      VLDL. Reduced amounts of ApoC-III will result in a larger representation of ApoE on the VLDL
      particle, and as a consequence, the ApoE mediated hydrolysis of Triglycerides is enhanced.
      Activation of PPAR-alpha leads to decrease production of ApoC-III, which in turn results in
      enhanced clearance of Triglycerides. Activation of PPAR-alpha also increases the synthesis of
      lipoprotein lipase, which increases Triglyceride catabolism. Gene expression for the
      synthesis of ApoA-I and ApoA-II is also enhanced by activation of PPAR-alpha, resulting in
      increase in HDL concentration. Fibric acid derivatives (Gemfibrozil and Fenofibrate) induce
      their Triglyceride lowering and HDL-C augmenting properties by binding to the PPAR-alpha
      nuclear receptor.

      TZDs are PPAR-gamma ligands that stimulate the gene expression of GLUT1 and GLUT4 (cellular
      glucose transport proteins) leading to increased insulin sensitivity in the target cells
      (15,16). The three PPAR receptors possess some degree of structural homology. Therefore,
      while TZDs have high affinity to PPAR-gamma, they may also bind to a lesser degree to
      PPAR-alpha or beta. Saliel and Olefsky (17) have determined in cell culture studies that
      Troglitazone can activate all three PPAR nuclear receptors. Lehmann et al. (18) observed in
      vitro that TZDs are high affinity ligands for PPAR-gamma yet also bind to PPAR-alpha (to a
      small degree). Binding PPAR-alpha would directly enhance the catabolism of Triglycerides
      (i.e. reduced ApoC-III plasma concentrations and increased lipoprotein lipase activity) and
      increase HDL-C plasma concentration through enhancing the expression of lipoprotein lipase
      and ApoA-I and ApoA-II. Therefore, administration of TZDs to non-diabetic normoglycemic
      individuals should not change plasma glucose concentrations, but by binding to PPAR-alpha it
      would result in decrease in the plasma concentration of ApoC-III, and an increase in ApoA-I
      and ApoA-II, with a subsequent rise in HDL-C and reduction in Triglyceride concentration.

      In a recent animal study assessing Rosiglitazone's mode of action on lipids using male
      Sprague-Dawley rats, serum total, free and HDL cholesterol concentrations were monitored. In
      rats given Rosiglitazone, serum Triglyceride levels decreased in a dose-dependent manner,
      dropping to less than 50% of that of the control rats at the highest dose tested (5 mg/kg/d).
      Serum glucose concentrations did not change after Rosiglitazone treatment, which is in
      agreement with previous studies showing that thiazolidinediones do not exert a hypoglycemic
      action in the normoglycemic, non-diabetic rat. (18)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment and increase in deployment overseas limiting follow up
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Triglyceride (TG) Levels Post Treatment</measure>
    <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
    <description>The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Percent Change in High-Density Lipoprotein (HDL) Levels</measure>
    <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
    <description>The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Percent Change in Low-Density Lipoprotein (LDL) Levels</measure>
    <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
    <description>The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Percent Change in Apolipoprotein A-I (Apo AI), Apolipoprotein A-II (Apo AII) and Apolipoprotein C-III (Apo CIII) Levels</measure>
    <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
    <description>Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at Initial Visit and Final Visit</measure>
    <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
    <description>The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Hypertriglyceridemia in Type 4 Hyperlipidemia</condition>
  <condition>Non Diabetic Subjects With Normoglycemia</condition>
  <arm_group>
    <arm_group_label>Rosiglitazone + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosiglitazone +Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Therapy Daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>Rosiglitazone 8mg daily for 12 weeks</description>
    <arm_group_label>Rosiglitazone + Placebo</arm_group_label>
    <arm_group_label>Rosiglitazone +Fenofibrate</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Rosiglitazone)</intervention_name>
    <description>Placebo (Rosiglitazone) 8mg daily for 12 weeks</description>
    <arm_group_label>Fenofibrate + Placebo</arm_group_label>
    <arm_group_label>Placebo Therapy Daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Fenofibrate)</intervention_name>
    <description>Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
    <arm_group_label>Rosiglitazone + Placebo</arm_group_label>
    <arm_group_label>Placebo Therapy Daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Fenofibrate 145 mg daily for 12 weeks</description>
    <arm_group_label>Fenofibrate + Placebo</arm_group_label>
    <arm_group_label>Rosiglitazone +Fenofibrate</arm_group_label>
    <other_name>Tricor, Triglide, Fenoglide, Lipofen and Lofibra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Fasting plasma glucose &lt;100 mg/dl

          2. Fasting LDL &lt;160 mg/dl and Triglyceride &lt;400 mg/dl.

        Exclusion criteria:

          1. Congestive heart failure

          2. Evidence of renal impairment (serum creatinine&gt; 1.4mg/dL)

          3. Liver disease (ALT and/or AST above the upper level of normal)

          4. Known diabetes mellitus or impaired fasting glucose (fasting glucose ≥ 100mg/dL)

          5. LDL of ≥160mg/dL and/or triglycerides of ≥400mg/dL

          6. Pregnant or breast feeding women

          7. Prior history of an acute coronary syndrome, myocardial infarction or
             revascularization procedures in the past

          8. Life-threatening disease with a survival prognosis &lt;3 years

          9. Inability to take rosiglitazone and/or fenofibrate

         10. Already on statin therapy or have been on statin therapy in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad m slim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laudino Castillo-rojas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer N Slim, DO</last_name>
    <role>Study Director</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism. 1997 Feb;46(2):192-8.</citation>
    <PMID>9030828</PMID>
  </reference>
  <reference>
    <citation>Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 1990 Oct;39(10):1056-62.</citation>
    <PMID>2120548</PMID>
  </reference>
  <reference>
    <citation>5. Troglitazone study group. The metabolic effects of troglitazone in non-insulin dependent diabetes. Diabetes 197; 46:Suppl 1:149A.</citation>
  </reference>
  <reference>
    <citation>Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994 Nov 3;331(18):1188-93.</citation>
    <PMID>7935656</PMID>
  </reference>
  <reference>
    <citation>Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.</citation>
    <PMID>11874944</PMID>
  </reference>
  <reference>
    <citation>Coresh J, Kwiterovich PO Jr. Small, dense low-density lipoprotein particles and coronary heart disease risk: A clear association with uncertain implications. JAMA. 1996 Sep 18;276(11):914-5.</citation>
    <PMID>8782642</PMID>
  </reference>
  <reference>
    <citation>Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996 Sep 18;276(11):882-8.</citation>
    <PMID>8782637</PMID>
  </reference>
  <reference>
    <citation>Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996 Sep 18;276(11):875-81.</citation>
    <PMID>8782636</PMID>
  </reference>
  <reference>
    <citation>11. Weinber, R.B. Lipoprotein metabolism: hormone regulation. Hosp. Prac 1987 :June' 15 :125-145.</citation>
  </reference>
  <reference>
    <citation>Dunn FL. Hyperlipidemia and diabetes. Med Clin North Am. 1982 Nov;66(6):1347-60. Review.</citation>
    <PMID>6755099</PMID>
  </reference>
  <reference>
    <citation>Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996 May;37(5):907-25. Review.</citation>
    <PMID>8725145</PMID>
  </reference>
  <reference>
    <citation>Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93. Review.</citation>
    <PMID>9808609</PMID>
  </reference>
  <reference>
    <citation>Bähr M, Spelleken M, Bock M, von Holtey M, Kiehn R, Eckel J. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia. 1996 Jul;39(7):766-74.</citation>
    <PMID>8817100</PMID>
  </reference>
  <reference>
    <citation>Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism. 1995 Aug;44(8):976-81.</citation>
    <PMID>7637655</PMID>
  </reference>
  <reference>
    <citation>Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6.</citation>
    <PMID>7768881</PMID>
  </reference>
  <reference>
    <citation>Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, Staels B. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol. 1997 Sep;17(9):1756-64.</citation>
    <PMID>9327774</PMID>
  </reference>
  <results_reference>
    <citation>1. American Diabetes association. Standards of medical care for patients with Diabetes Mellitus. Diabetes Care 1997 ;20 : Suppl 1 :55-513.</citation>
  </results_reference>
  <results_reference>
    <citation>Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 1994 Dec;43(12):1435-9.</citation>
    <PMID>7958495</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <results_first_submitted>February 6, 2013</results_first_submitted>
  <results_first_submitted_qc>January 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2014</results_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brooke Army Medical Center</investigator_affiliation>
    <investigator_full_name>Ahmad Slim</investigator_full_name>
    <investigator_title>Director, Cardiovascular Research</investigator_title>
  </responsible_party>
  <keyword>Type 4 hyperlipidemia</keyword>
  <keyword>Rosiglitazone</keyword>
  <keyword>Fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rosiglitazone + Placebo</title>
          <description>Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Fenofibrate + Placebo</title>
          <description>Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks</description>
        </group>
        <group group_id="P3">
          <title>Rosiglitazone + Fenofibrate</title>
          <description>Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo Therapy Daily</title>
          <description>Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosiglitazone/Fenofibrate Therapy Daily</title>
          <description>Rosiglitazone 8mg once daily and Fenofibrate 145mg once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Fenofibrate + Placebo</title>
          <description>Fenofibrate 145mg once daily for 12 weeks and Placebo (Rosiglitazone 8mg once daily)</description>
        </group>
        <group group_id="B3">
          <title>Rosiglitazone + Placebo</title>
          <description>Rosiglitazone 8mg once daily and Placebo ( Fenofibrate 145mg once daily)</description>
        </group>
        <group group_id="B4">
          <title>Placebo Therapy Daily</title>
          <description>Placebo (Rosiglitazone 8mg once daily) and placebo (Fenofibrate 145 mg once daily) for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="9.5"/>
                    <measurement group_id="B2" value="61.2" spread="11.6"/>
                    <measurement group_id="B3" value="57.3" spread="8.4"/>
                    <measurement group_id="B4" value="57.4" spread="11.1"/>
                    <measurement group_id="B5" value="56" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Triglyceride (TG) Levels Post Treatment</title>
        <description>The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol</description>
        <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
        <population>Mean percent change post treatment ( unit %). TG was measured using mg/dL units</population>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone + Placebo</title>
            <description>Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate + Placebo</title>
            <description>Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone +Fenofibrate</title>
            <description>Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Therapy Daily</title>
            <description>Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglyceride (TG) Levels Post Treatment</title>
          <description>The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol</description>
          <population>Mean percent change post treatment ( unit %). TG was measured using mg/dL units</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="48.9"/>
                    <measurement group_id="O2" value="-2.2" spread="26"/>
                    <measurement group_id="O3" value="20" spread="36.5"/>
                    <measurement group_id="O4" value="7.6" spread="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Percent Change in High-Density Lipoprotein (HDL) Levels</title>
        <description>The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol</description>
        <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone and Placebo</title>
            <description>Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate + Placebo</title>
            <description>Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone +Fenofibrate</title>
            <description>Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Therapy Daily</title>
            <description>Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Percent Change in High-Density Lipoprotein (HDL) Levels</title>
          <description>The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="24.6"/>
                    <measurement group_id="O2" value="14.5" spread="21.6"/>
                    <measurement group_id="O3" value="5.8" spread="16.4"/>
                    <measurement group_id="O4" value="1.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Percent Change in Low-Density Lipoprotein (LDL) Levels</title>
        <description>The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol</description>
        <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone + Placebo</title>
            <description>Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate + Placebo</title>
            <description>Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone + Fenofibrate</title>
            <description>Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Therapy Daily</title>
            <description>Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Percent Change in Low-Density Lipoprotein (LDL) Levels</title>
          <description>The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="27.4"/>
                    <measurement group_id="O2" value="2.6" spread="29.3"/>
                    <measurement group_id="O3" value="37.3" spread="141.6"/>
                    <measurement group_id="O4" value="13.7" spread="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Percent Change in Apolipoprotein A-I (Apo AI), Apolipoprotein A-II (Apo AII) and Apolipoprotein C-III (Apo CIII) Levels</title>
        <description>Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided</description>
        <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone + Placebo</title>
            <description>Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate + Placebo</title>
            <description>Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone +Fenofibrate</title>
            <description>Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Therapy Daily</title>
            <description>Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Percent Change in Apolipoprotein A-I (Apo AI), Apolipoprotein A-II (Apo AII) and Apolipoprotein C-III (Apo CIII) Levels</title>
          <description>Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided</description>
          <units>% Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Apo AI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-34" upper_limit="9"/>
                    <measurement group_id="O2" value="13" lower_limit="9" upper_limit="18"/>
                    <measurement group_id="O3" value="1" lower_limit="-4" upper_limit="12"/>
                    <measurement group_id="O4" value="5" lower_limit="-11" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo AII</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.25" lower_limit="4.90" upper_limit="11.50"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.7" upper_limit="7.4"/>
                    <measurement group_id="O3" value="7.2" lower_limit="-2.3" upper_limit="8"/>
                    <measurement group_id="O4" value="-3.5" lower_limit="-3.6" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo CIII</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="0.00" upper_limit="1.80"/>
                    <measurement group_id="O2" value="-4.35" lower_limit="-7.4" upper_limit="-2.2"/>
                    <measurement group_id="O3" value="-5.3" lower_limit="-6.7" upper_limit="-3"/>
                    <measurement group_id="O4" value="-2.3" lower_limit="-3.7" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Levels of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at Initial Visit and Final Visit</title>
        <description>The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively.</description>
        <time_frame>12 weeks from initial visit (day 0) to final visit (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone + Placebo</title>
            <description>Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate + Placebo</title>
            <description>Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone +Fenofibrate</title>
            <description>Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo Therapy Daily</title>
            <description>Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Levels of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at Initial Visit and Final Visit</title>
          <description>The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST 1 (aspartate aminotransferase [10-35 U/L])</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" spread="11.091"/>
                    <measurement group_id="O2" value="25.25" spread="7.517"/>
                    <measurement group_id="O3" value="24.30" spread="5.870"/>
                    <measurement group_id="O4" value="19.88" spread="5.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST 12 (aspartate aminotransferase [15-37 U/L])</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.29" spread="9.810"/>
                    <measurement group_id="O2" value="26.50" spread="7.964"/>
                    <measurement group_id="O3" value="19.70" spread="2.584"/>
                    <measurement group_id="O4" value="17.88" spread="6.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT 1 (alanine aminotransferase [6-60 U/L])</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.14" spread="13.957"/>
                    <measurement group_id="O2" value="25.88" spread="15.394"/>
                    <measurement group_id="O3" value="24.10" spread="10.429"/>
                    <measurement group_id="O4" value="20.88" spread="6.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT 12 (alanine aminotransferase [6-60 U/L])</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.43" spread="10.358"/>
                    <measurement group_id="O2" value="26.38" spread="11.916"/>
                    <measurement group_id="O3" value="21.10" spread="8.647"/>
                    <measurement group_id="O4" value="14.88" spread="3.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>These are the adverse events reported during the monitoring period in 41 initial participants contributing to partially to drop out of 7 participants and the final data reported in the results section of only 34 participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rosiglitazone/Fenofibrate Therapy Daily</title>
          <description>Rosiglitazone 8mg po daily + Fenofibrate 145 mg po daily for 12 weeks
These are the adverse events reported in population who continued the 12 weeks of therapy as well as the population that dropped out.</description>
        </group>
        <group group_id="E2">
          <title>Rosiglitazone + Placebo</title>
          <description>Rosiglitazone 8mg po daily + Placebo (Fenofibrate 145 mg po daily) for 12 weeks
These are the adverse events reported in population who continued the 12 weeks of therapy as well as the population that dropped out.</description>
        </group>
        <group group_id="E3">
          <title>Fenofibrate + Placebo</title>
          <description>Fenofibrate 145 mg po daily for 12 weeks= Placebo (Rosiglitazone 8mg po daily)
These are the adverse events reported in population who continued the 12 weeks of therapy as well as the population that dropped out.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Therapy Daily</title>
          <description>Rosiglitazone (placebo) once daily and Fenofibrate (placebo)once daily for 12 weeks
These are the adverse events reported in population who continued the 12 weeks of therapy as well as the population that dropped out.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pressure behind left eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Severe Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Severe sinusitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Aching legs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Stiff Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hip pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Swollen Ankles</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>First, the study was terminated early per FDA recommendations restricting rosiglitazone use. Second, recruitment of patients was slow due to deployment restraints.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ahmad Slim, MD</name_or_title>
      <organization>Brooke Army Medical Center</organization>
      <phone>2109164717</phone>
      <email>ahmad.slim@us.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

